Company: WHWK
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001628280-25-023932
Chunk: 110

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 3
Chunk 110
---
 Therapies or any of our product candidates that we may develop or the inability to do so at acceptable prices;

•the entry into, or termination of, key agreements, including key licensing, supply or collaboration agreements;

•adverse regulatory authority decisions;

•the initiation of material developments in, or conclusion of, disputes or litigation to enforce or defend any of our intellectual property rights or defend against the intellectual property rights of others;

•changes in laws or regulations applicable to the ADC Therapies or any of our product candidates that we may develop;

•announcements by commercial partners or competitors of new commercial products, clinical progress (or the lack thereof), significant contracts, commercial relationships, or capital commitments;

•failure to meet or exceed financial and development projections we may provide to the public;

•failure to meet or exceed the financial and development projections of the investment community;

•the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community;

•general market conditions and other factors unrelated to our operating performance or the operating performance of our competitors, including turmoil in the global banking system, deteriorating market conditions due to investor concerns regarding inflation and conflicts in Ukraine and the Middle East;

•adverse publicity relating to our markets, including with respect to other products and potential products in such markets;

•the introduction of technological innovations or new therapies competing with our products and potential products;

•announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors; 

•disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies;

•the hiring or loss of key employees;

•significant lawsuits, including patent or stockholder litigation;

•if securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our business and stock;

•changes in the market valuations of similar companies;

•general and industry-specific economic conditions potentially affecting our research and development expenditures;

•sales of our common stock by us or our stockholders in the future, or the anticipation thereof;

•trading volume of our common stock;

•changes in the structure of health care payment systems;

•adverse regulatory decisions;

•trading volume of our common stock; and

•period-to-period fluctuations in our financial results.

Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies or the biotechnology sector. These broad market fluctuations may also adversely